Product Liability Attorney Announces New Diabetes Drug Website

July 2, 2013

Rudolph F.X. Migliore, P.C. a defective drug law firm has launched a new website discussing complications arising from several popular diabetes drugs and lawsuits concerning these drugs.

Commack, NY (PRWEB) July 02, 2013

The law firm of Rudolph F.X. Migliore P.C. is pleased to announce the launch of a new website, http://www.diabetesdrugproblems.com/. The website provides information about type 2 diabetes drugs that the U.S. Food and Drug Administration has warned may be tied to pancreatic cancer, thyroid cancer and/or bladder cancer and severe pancreatitis. *1 *2

Product liability attorney Rudy Migliore explained, “Risks associated with diabetes drugs can be very frightening, especially for one who is already dealing with a major illness. When patients who have been taking the drugs experience serious conditions, they are unsure of where to turn for help.” He continued, “Our new website gives people the assurance they need that legal help is available to evaluate health complications arising from diabetes drugs and determine whether there are grounds for a lawsuit.”

The New York law firm regularly tackles cases involving defective prescription drugs and helps clients obtain compensation for serious injury. The firm has worked with nationally recognized co-counsel to recover major verdicts for clients for more than three decades.

If you or someone you care about has developed a serious condition after taking a diabetes drug, visit our diabetes drug website or call (631) 543-3663 to arrange a confidential consultation. There is no fee to find out if you have grounds for a diabetes drug-related claim.

About Rudolph F.X. Migliore, P.C.: Located on Long Island, Rudolph F. X. Migliore, P.C. is a civil and criminal litigation firm. Our attorneys represent victims of serious personal injury, including dangerous prescription drugs, mesothelioma, defective products and medical malpractice.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10886724.htm

Source: prweb

comments powered by Disqus